F S&P 500
5,252.50 +6.25 (+0.12%) F Dow Jones
39,670.00 +28.00 (+0.07%) F Nasdaq
18,290.25 +35.25 (+0.19%) E-mini Russell 2000 Index Futur
2,075.80 +7.90 (+0.38%) Petróleo
78.54 +0.28 (+0.36%) Oro
2,347.30 -27.70 (-1.17%)
Immunome, Inc. (IMNM)
Fuera de horario:
Immunome, Inc.
18702 N. Creek Parkway
Suite 100
Bothell, WA 98011
United States
610-321-3700
https://immunome.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 55
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Clay B. Siegall Ph.D. | President, CEO & Chairman | 1.43M | N/D | 1961 |
| Dr. Jack Higgins Ph.D. | Chief Scientific Officer | 956.34k | N/D | 1980 |
| Dr. Robert J. Lechleider M.D. | Chief Medical Officer | 512.49k | N/D | 1961 |
| Mr. Max Rosett | Interim CFO & Executive VP of Operations | N/D | N/D | 1990 |
| Mr. Robert Lapetina | Principal Accounting Officer | N/D | N/D | 1975 |
| Ms. Sandra G. Stoneman Esq., J.D. | Chief Legal Officer, General Counsel & Corporate Secretary | 443.43k | N/D | 1974 |
| Mr. Bruce Turner M.D., Ph.D. | Chief Strategy Officer | N/D | N/D | 1964 |
| Mr. Kinney Horn | Chief Business Officer | N/D | N/D | 1975 |
Descripción
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Gestión corporativa
La calificación ISS Governance QuickScore de Immunome, Inc. a partir del 1 de mayo de 2024 es 10. Las puntuaciones principales son Auditoría: 10; Junta: 10; Derechos del accionista: 7; Compensación: 8.
